Nuvation Bio, a stealth biotechnology company developing proprietary therapies focused on oncology, raised $275m in a Series A financing led by Omega. The round was led, structured and syndicated by Omega Funds and included participation from leading biotechnology investors including Aisling Capital, Altitude Life Science Ventures, The Baupost Group, Boxer Capital of the Tavistock Group, EDBI (global Asian-based Investor), ECOR1 Capital, Fidelity Management and Research Company, Pavilion Capital, Perceptive Advisors, Redmile Group, Surveyor Capital (a Citadel Company) and other institutional investors. "The whole Omega Funds' team has been thrilled to partner with David on the launch and Series A syndication of Nuvation Bio and thanks to deal leads Richard Lim and Michelle Doig for their efforts executing this transaction. The breadth and depth of Nuvation Bio's innovative pipeline demands a large initial investment. By syndicating one of the largest-ever Series A biotech financings, David and his exceptional team are well-positioned to advance Nuvation Bio's deep portfolio of therapies focused on dramatically improving the standard of care for those living with cancer," Otello Stampacchia, Ph.D., Founder and Managing Director of Omega Funds.